Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD5024 cream placebo
- Development stage
- Phase 2
- Lead developer
- Galderma
- Administration
- Topical
01
Overview
CD5024 cream placebo is the inactive vehicle control used in clinical trials for CD5024 (ivermectin) 1% cream, a topical treatment developed by Galderma R&D. It is formulated to be physically and sensorially identical to the active 1% cream but lacks the active pharmaceutical ingredient. In the context of acne vulgaris research, this placebo is utilized in randomized, investigator-blinded, split-face studies to provide a baseline for comparing the efficacy and safety of the active treatment, effectively isolating the pharmacological effects of ivermectin from the potential effects of the cream's excipients.
- Other names
- CD5024 vehicleCD-5024 vehicleCD 5024 vehicleVehicle of CD5024 1% cream
Beyond the preview
Go deeper on CD5024 cream placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD5024 cream placebo.